3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other
1
Head & Neck
1
Conditions
Stomatitis
1
Neuroendocrine Tumors
1
Neoplasms
1
Mucositis
1
Mouth Neoplasms
1
Lymphoma
1
Lung Neoplasms
1
Head and Neck Neoplasms
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Carcinoma, Small Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cisplatin
7
Cetuximab
6
Radiotherapy, Intensity-Modulated
4
pembrolizumab
3
durvalumab
3
Radiotherapy
2
Radiation
2
Observation
2
Drug Therapy
2
Celecoxib
2
Bupropion
2
130-nm albumin-bound paclitaxel
2
trametinib
1
sodium thiosulfate
1
gluconic acid
1
ficlatuzumab
1
Zinc
1
Watchful Waiting
1
Varenicline
1
Transcutaneous Electric Nerve Stimulation
1
Tobacco Use Cessation Devices
1
Tadalafil
1
Sirolimus
1
RRx-001
1
Psychiatric Rehabilitation
1
Polymerase Chain Reaction
1
Pilocarpine
1
Photochemotherapy
1
Periodontal Debridement
1
Oral Hygiene
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Has results
×
Mouth Neoplasms
×
RRx-001
×
Clear all
NCT03515538
2024-11-04
PREVLAR
EpicentRx, Inc.
Phase 2
Completed
53 enrolled
15 charts